Citadel Advisors
CYTO

Citadel Advisors’s Altamira Therapeutics Ltd CYTO Stock Holding History

Citadel Advisors’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35
Closed -$50K – 14941
2021
Q2 		$50K Sell
35
-40
-53% -$54.9K ﹤0.01% 13338
2021
Q1 		$104K Buy
+75
New +$101K ﹤0.01% 12443

Other funds holding CYTO

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's CYTO Position: Q4 2024 in Review

Citadel Advisors sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2024, closing a stake of 14,802 shares — an estimated $9.35K sold.

Citadel Advisors first reported a position in CYTO in Q1 2018 and held it in 10 quarters. The position peaked at $159K in Q1 2021. 2 funds tracked by Wall St. Rank hold CYTO as of Q4 2024.

  • Citadel Advisors reported no remaining Altamira Therapeutics Ltd position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 14,802 Altamira Therapeutics Ltd shares in Q4 2024, an estimated $9.35K.
  • Citadel Advisors first reported a position in Altamira Therapeutics Ltd in Q1 2018 and held it in 10 quarters.
  • Citadel Advisors's Altamira Therapeutics Ltd position peaked at $159K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.